A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)
ACTIVE_NOT_RECRUITING
Status
Conditions
- VHL - Von Hippel-Lindau Syndrome
- VHL Gene Mutation
- VHL Syndrome
- VHL Gene Inactivation
- VHL-Associated Renal Cell Carcinoma
- VHL-Associated Clear Cell Renal Cell Carcinoma
Interventions
Sponsor
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)